Literature DB >> 25344802

Role of MTA1 in cancer progression and metastasis.

Nirmalya Sen1, Bin Gui, Rakesh Kumar.   

Abstract

The MTA1 protein contributes to the process of cancer progression and metastasis through multiple genes and protein targets and interacting proteins with roles in transformation, anchorage-independent growth, invasion, survival, DNA repair, angiogenesis, hormone independence, metastasis, and therapeutic resistance. Because the roles and clinical significance of MTA proteins in human cancer are discussed by other contributors in this issue, this review will focus on our current understanding of the underlying principles of action behind the biological effects of MTA1. MTA proteins control a spectrum of cancer-promoting processes by modulating the expression of target genes and/or the activity of MTA-interacting proteins. In the case of MTA1, these functions are manifested through posttranslational modifications of MTA1 in response to upstream signals, MTA1 interaction with binding proteins, and the expression of target gene products. Studies delineating the molecular basis of dual functionality of MTA1 reveal that the functions of MTA1-chromatin-modifying complexes in the context of target gene regulation are dynamic in nature. The nature and targets of MTA1-chromatin-modifying complexes are also governed by the dynamic plasticity of the nucleosome landscape as well as kinetics of activation and inactivation of enzymes responsible for posttranslational modifications on the MTA1 protein. These broadly applicable functions also explain why MTA1 may be a "hub" gene in cancer. Because the deregulation of enzymes and their substrates with roles in MTA1 biology is not necessarily limited to cancer, we speculate that the lessons from MTA1 as a prototype dual master coregulator will be relevant for other human diseases. In this context, the concept of the dynamic nature of corepressor versus coactivator complexes and the MTA1 proteome as a function of time to signal is likely to be generally applicable to other multiprotein regulatory complexes in living systems.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344802      PMCID: PMC4245458          DOI: 10.1007/s10555-014-9515-3

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  61 in total

1.  MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.

Authors:  Naoyuki Fujita; David L Jaye; Masahiro Kajita; Cissy Geigerman; Carlos S Moreno; Paul A Wade
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

2.  Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells.

Authors:  Rakesh Kumar; Seetharaman Balasenthil; Suresh B Pakala; Suresh K Rayala; Aysegul A Sahin; Kazufumi Ohshiro
Journal:  Cancer Res       Date:  2010-08-15       Impact factor: 12.701

3.  MTA1, a transcriptional activator of breast cancer amplified sequence 3.

Authors:  Anupama E Gururaj; Rajesh R Singh; Suresh K Rayala; Caroline Holm; Petra den Hollander; Hao Zhang; Seetharaman Balasenthil; Amjad H Talukder; Goran Landberg; Rakesh Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

4.  Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma2, an estrogen-responsive kinase.

Authors:  Sandip K Mishra; Zhibo Yang; Abhijit Mazumdar; Amjad H Talukder; Louise Larose; Rakesh Kumar
Journal:  Oncogene       Date:  2004-05-27       Impact factor: 9.867

5.  A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses.

Authors:  Y Toh; S D Pencil; G L Nicolson
Journal:  J Biol Chem       Date:  1994-09-16       Impact factor: 5.157

6.  A core chromatin remodeling factor instructs global chromatin signaling through multivalent reading of nucleosome codes.

Authors:  Sujit S Nair; Da-Qiang Li; Rakesh Kumar
Journal:  Mol Cell       Date:  2013-01-24       Impact factor: 17.970

7.  Metastasis-associated protein 1 promotes tumor invasion by downregulation of E-cadherin.

Authors:  Wenhao Weng; Jiayi Yin; Yue Zhang; Jin Qiu; Xinghe Wang
Journal:  Int J Oncol       Date:  2014-01-10       Impact factor: 5.650

8.  Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway.

Authors:  Da-Qiang Li; Suresh B Pakala; Sirigiri Divijendra Natha Reddy; Kazufumi Ohshiro; Shao-Hua Peng; Yi Lian; Sidney W Fu; Rakesh Kumar
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

Review 9.  Emerging roles of MTA family members in human cancers.

Authors:  Rakesh Kumar; Rui-An Wang; Rozita Bagheri-Yarmand
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

10.  MTA1 overexpression induces cisplatin resistance in nasopharyngeal carcinoma by promoting cancer stem cells properties.

Authors:  Xiaohua Feng; Qianbing Zhang; Songxin Xia; Bing Xia; Yue Zhang; Xubin Deng; Wenmei Su; Jianqing Huang
Journal:  Mol Cells       Date:  2014-09-22       Impact factor: 5.034

View more
  37 in total

Review 1.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

2.  Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells.

Authors:  H Marzook; S Deivendran; B George; G Reshmi; T R Santhoshkumar; R Kumar; M R Pillai
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

3.  Interplay between 15-lipoxygenase-1 and metastasis-associated antigen 1 in the metastatic potential of colorectal cancer.

Authors:  S Tunçer; S Tunçay Çağatay; A G Keşküş; M Çolakoğlu; Ö Konu; S Banerjee
Journal:  Cell Prolif       Date:  2016-06-19       Impact factor: 6.831

4.  MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.

Authors:  L Deng; J Tang; H Yang; C Cheng; S Lu; R Jiang; B Sun
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

Review 5.  Structure, expression and functions of MTA genes.

Authors:  Rakesh Kumar; Rui-An Wang
Journal:  Gene       Date:  2016-02-09       Impact factor: 3.688

6.  MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Hidekazu Takahashi; Yota Yasumizu; Wei Li; Caining Jin; Mark D Long; Qiang Hu; Song Liu; Atsushi Fushimi; Nami Yamashita; Ling Kui; Deli Hong; Masaaki Yamamoto; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Mehmet K Samur; Donald Kufe
Journal:  Cancer Res       Date:  2019-09-13       Impact factor: 12.701

Review 7.  SIX3 function in cancer: progression and comprehensive analysis.

Authors:  Tian-Liang Ma; Peng Zhu; Jing-Xian Chen; Yi-He Hu; Jie Xie
Journal:  Cancer Gene Ther       Date:  2022-06-28       Impact factor: 5.987

8.  RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis.

Authors:  Xin Yin; Xu Teng; Tianyu Ma; Tianshu Yang; Jingyao Zhang; Miaomiao Huo; Wei Liu; Yunkai Yang; Baowen Yuan; Hefen Yu; Wei Huang; Yan Wang
Journal:  Cell Death Differ       Date:  2022-05-09       Impact factor: 15.828

9.  CUL4B Promotes Breast Carcinogenesis by Coordinating with Transcriptional Repressor Complexes in Response to Hypoxia Signaling Pathway.

Authors:  Wei Huang; Jingyao Zhang; Miaomiao Huo; Jie Gao; Tianshu Yang; Xin Yin; Pei Wang; Shuai Leng; Dandan Feng; Yang Chen; Yang Yang; Yan Wang
Journal:  Adv Sci (Weinh)       Date:  2021-03-16       Impact factor: 16.806

10.  Identification of Susceptible Genes for Chronic Obstructive Pulmonary Disease with Lung Adenocarcinoma by Weighted Gene Co-Expression Network Analysis.

Authors:  Ping Li; Youyu Wang; Xiaoli Wang; Lin Liu; Lei Chen
Journal:  Onco Targets Ther       Date:  2021-06-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.